ONO 1301

ONO 1301 (ONO-AP 500-02), a prostaglandin (PG) I2 mimetic, is an orally active, long-acting prostacyclin agonist with thromboxane-synthase inhibitory activity. ONO 1301 promotes production of hepatocyte growth factor (HGF) from various cell types and ameliorates ischemia-induced left ventricle dysfunction in the mouse, rat and pig[1][2][3].

Product Specifications

CAS Number

[176391-41-6]

Product Name Alternative

ONO-AP 500-02

UNSPSC

12352005

Hazard Statement

H302-H312-H332

Target

Prostaglandin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/ono-1301.html

Purity

99.02

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

OC(COC1=C2C(C(CCO/N=C(C3=CN=CC=C3)\C4=CC=CC=C4)=CCC2)=CC=C1)=O

Molecular Formula

C26H24N2O4

Molecular Weight

428.49

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P363-P501

References & Citations

[1]Hirata Y, et al. Beneficial effect of a synthetic prostacyclin agonist, ONO-1301, in rat autoimmune myocarditis model. Eur J Pharmacol. 2013;699 (1-3) :81-87. |[2]Kashiwagi H, et al. The novel prostaglandin I2 mimetic ONO-1301 escapes desensitization in an antiplatelet effect due to its inhibitory action on thromboxane A2 synthesis in mice. J Pharmacol Exp Ther. 2015;353 (2) :269-278. |[3]Kanayama S, et al. ONO-1301 Enhances in vitro Osteoblast Differentiation and in vivo Bone Formation Induced by Bone Morphogenetic Protein. Spine (Phila Pa 1976) . 2018;43 (11) :E616-E624.